Open Daily: 10am - 10pm | Alley door pickup 10am - 7pm 3038 Hennepin Ave Minneapolis, MN
612-822-4611

  • Open Daily: 10am - 10pm
    Alley-side Pickup: 10am - 7pm

    3038 Hennepin Ave Minneapolis, MN
    612-822-4611

Open Daily: 10am - 10pm | Alley-side Pickup: 10am - 7pm
3038 Hennepin Ave Minneapolis, MN
612-822-4611
A Primer of Molecular Biology

A Primer of Molecular Biology

Roberts, Robert

Paperback

Series: Current Topics in Cardiology

Gifts & Stationery GeneralGeneral ReferenceGeneral Science

ISBN10: 1468466828
ISBN13: 9781468466829
Publisher: Springer
Published: Apr 11 2013
Pages: 202
Weight: 0.86
Height: 0.46 Width: 7.00 Depth: 10.00
Language: English
In arecent plenary address to the American College of Cardiology, Dr. Leroy Hood stated that he expected the application of the techniques of recombinant DNA and molecular biology to medicine would advance the field more in the next twenty years than all of the progress that has been made in the past 2,000 years. Cardiology, as a discipline, has been one of the last to embrace the techniques of molecular biology, yet the advances made in the past five years have indeed been dramatic. Throm- bolytic therapy, introduced with a bang through the use of recombinant tissue plasminogen activator (rt-PA), is now part of the routine arma- mentarium in the treatment of patients with acute myocardial infarction. Tissue plasminogen activator was the first drug made with the use of recombinant DNA techniques to be used in cardiology and was approved by the Food and Drug Administration (FDA) in 1989. In the short time since then, five other drugs made by these techniques have been added to the treatment of patients with ischemic heart disease-hirudin, su- peroxide dismutase, urokinase, prourokinase, and multiple mutant forms of rt-PA. The FDA has approved fewer than 100 drugs that are made by recombinant DNA techniques, but estimates that by the year 2000 over 50% of all drugs will be made by these techniques.

Also in

General Science

View All